See more : Applied UV, Inc. (AUVIP) Income Statement Analysis – Financial Results
Complete financial analysis of Dong Sung Bio Pharm.Co.,Ltd. (002210.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Dong Sung Bio Pharm.Co.,Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Besqab AB (publ) (BESQ.ST) Income Statement Analysis – Financial Results
- Moonpig Group PLC (MOON.L) Income Statement Analysis – Financial Results
- OrganiGram Holdings Inc. (OGI) Income Statement Analysis – Financial Results
- asknet Solutions AG (ASKN.DE) Income Statement Analysis – Financial Results
- ALPEK, S.A.B. de C.V. (ALPEKA.MX) Income Statement Analysis – Financial Results
Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://dongsung-pharm.com
About Dong Sung Bio Pharm.Co.,Ltd.
Dong Sung Bio Pharm.Co.,Ltd. engages in the pharmaceuticals, cosmetics, hair dye, and photodynamic therapy businesses in South Korea. It offers OTC drugs, such as liver disease treatment, climacterium, skin disease, obesity, digestive, gingival, alopecia, antipyretic, analgesic, anti-inflammatory, respiratory, scar-recovery, sleep inducer, antidiarrhotica, antiemetic, antiviral, blood circulation enhancer, antifungal, and anti-histamine drugs, as well as keratin softeners, optic nutrition supplements, and vitamins. The company also provides ETC drugs, including endocrine, gastrointestinal, circulatory, neuropsychologic, tumor, analgesic/anti-inflammation, dermato-urinary, anti-viral, antibiotic, antifungal, anti-histamine, and respiratory drugs, as well as steroids and eye drops. In addition, it offers hair dyeing agents, health functional foods, medical devices, daily supplies, muscle taping products, disinfectants, toothpastes, anti-hair loss and hair increase shampoos, sanitary pads, and other products. The company was founded in 1957 and is headquartered in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.59B | 93.33B | 84.41B | 87.80B | 86.54B | 91.91B | 82.39B | 79.72B | 74.66B | 73.16B | 75.18B | 84.58B | 78.44B | 71.93B | 68.72B | 62.23B | 60.32B |
| Cost of Revenue | 47.22B | 51.27B | 50.86B | 53.65B | 53.46B | 56.72B | 46.28B | 42.62B | 38.18B | 37.89B | 36.21B | 42.06B | 33.02B | 31.92B | 27.61B | 25.27B | 23.74B |
| Gross Profit | 41.37B | 42.06B | 33.54B | 34.15B | 33.08B | 35.19B | 36.10B | 37.10B | 36.48B | 35.26B | 38.96B | 42.52B | 45.42B | 40.01B | 41.11B | 36.96B | 36.58B |
| Gross Profit Ratio | 46.70% | 45.06% | 39.74% | 38.89% | 38.22% | 38.29% | 43.82% | 46.53% | 48.86% | 48.20% | 51.83% | 50.28% | 57.90% | 55.62% | 59.82% | 59.39% | 60.64% |
| Research & Development | 4.17B | 4.12B | 3.40B | 3.37B | 3.10B | 3.00B | 2.46B | 2.35B | 2.48B | 2.48B | 2.46B | 2.20B | 377.33M | 193.10M | 332.15M | 252.34M | 169.72M |
| General & Administrative | 1.89B | 1.83B | 1.70B | 1.61B | 1.93B | 1.78B | 3.09B | 3.13B | 3.26B | 2.81B | 2.83B | 2.24B | 3.17B | 3.22B | 3.55B | 4.33B | 3.13B |
| Selling & Marketing | 24.76B | 27.00B | 21.38B | 21.84B | 21.75B | 19.37B | 18.00B | 19.47B | 19.77B | 19.84B | 24.18B | 25.46B | 25.43B | 25.87B | 24.98B | 20.64B | 20.21B |
| SG&A | 26.66B | 28.84B | 23.08B | 23.45B | 23.68B | 21.15B | 21.09B | 22.60B | 23.03B | 22.65B | 27.01B | 27.70B | 28.60B | 29.09B | 28.53B | 24.97B | 23.34B |
| Other Expenses | 9.95B | 12.20B | 12.36B | 11.00B | 13.82B | 243.47M | 327.56M | 796.94M | 479.59M | -977.72M | 420.24M | 1.34B | 494.89M | -618.70M | 372.31M | 202.60M | 206.50M |
| Operating Expenses | 40.77B | 45.15B | 38.84B | 37.82B | 40.61B | 37.00B | 35.15B | 39.39B | 35.28B | 37.09B | 40.93B | 39.27B | 42.31B | 43.15B | 39.98B | 35.35B | 34.93B |
| Cost & Expenses | 88.00B | 96.43B | 89.71B | 91.47B | 94.07B | 93.72B | 81.43B | 82.01B | 73.46B | 74.99B | 77.14B | 81.33B | 75.33B | 75.07B | 67.59B | 60.62B | 58.67B |
| Interest Income | 63.26M | 47.07M | 76.67M | 25.52M | 60.36M | 23.60M | 5.89M | 7.79M | 12.08M | 155.06M | 72.69M | 47.31M | 98.47M | 347.48M | 260.91M | 548.17M | 349.07M |
| Interest Expense | 2.24B | 1.31B | 712.20M | 850.30M | 1.40B | 1.69B | 1.47B | 1.40B | 1.42B | 1.56B | 1.81B | 2.28B | 2.00B | 2.08B | 1.70B | 1.83B | 1.97B |
| Depreciation & Amortization | 2.05B | 2.07B | 1.94B | 1.81B | 2.04B | 1.91B | 1.74B | 1.57B | 1.61B | 1.54B | 1.46B | 1.59B | 1.51B | 1.56B | 1.32B | 1.39B | 1.47B |
| EBITDA | 3.42B | 1.53B | -1.73B | -8.14B | -5.33B | -3.09B | 2.64B | 425.90M | 3.03B | 37.80M | 163.44M | 7.47B | 5.26B | -1.14B | 3.69B | 8.45B | 3.74B |
| EBITDA Ratio | 3.86% | 0.08% | -1.56% | -1.61% | -4.81% | 0.87% | 2.75% | -0.90% | 4.05% | -1.25% | 0.16% | 8.14% | 6.49% | -2.93% | 4.24% | 7.62% | 6.20% |
| Operating Income | 596.40M | -2.04B | -5.30B | -3.67B | -7.53B | -1.81B | 955.13M | -2.29B | 1.20B | -1.83B | -1.97B | 3.25B | 3.60B | -3.15B | 1.13B | 1.61B | 1.65B |
| Operating Income Ratio | 0.67% | -2.19% | -6.28% | -4.18% | -8.70% | -1.97% | 1.16% | -2.87% | 1.60% | -2.50% | -2.62% | 3.85% | 4.58% | -4.37% | 1.64% | 2.58% | 2.74% |
| Total Other Income/Expenses | -1.46B | 191.20M | 919.71M | -7.14B | -1.23B | -4.89B | -1.52B | -253.43M | -452.82M | -1.16B | -1.15B | -494.00M | -1.85B | -1.91B | -453.96M | 3.63B | 1.82B |
| Income Before Tax | -865.89M | -1.85B | -4.38B | -10.81B | -8.77B | -6.69B | -566.25M | -2.54B | 744.08M | -3.00B | -3.11B | 3.59B | 1.75B | -5.05B | 675.99M | 5.24B | 3.47B |
| Income Before Tax Ratio | -0.98% | -1.98% | -5.19% | -12.31% | -10.13% | -7.28% | -0.69% | -3.19% | 1.00% | -4.09% | -4.14% | 4.25% | 2.23% | -7.02% | 0.98% | 8.41% | 5.76% |
| Income Tax Expense | 1.21B | 271.07M | -66.51M | 3.27B | -380.34M | -948.52M | -367.99M | -882.61M | 289.24M | 7.95B | -1.13B | 399.78M | 47.50M | 2.89B | 107.56M | 1.58B | 815.59M |
| Net Income | -2.07B | -2.12B | -4.31B | -14.08B | -8.39B | -5.74B | -198.26M | -1.66B | 454.84M | -10.95B | -1.99B | 3.19B | 1.70B | -7.94B | 568.43M | 3.66B | 2.66B |
| Net Income Ratio | -2.34% | -2.27% | -5.11% | -16.04% | -9.69% | -6.25% | -0.24% | -2.08% | 0.61% | -14.96% | -2.64% | 3.77% | 2.17% | -11.04% | 0.83% | 5.88% | 4.40% |
| EPS | -90.70 | -92.23 | -184.52 | -599.87 | -363.57 | -293.00 | -10.00 | -83.29 | 23.00 | -589.00 | -110.00 | 181.00 | 96.00 | -441.00 | 31.00 | 201.00 | 152.60 |
| EPS Diluted | -86.74 | -87.74 | -184.29 | -599.87 | -363.57 | -293.00 | -10.00 | -83.00 | 23.00 | -579.00 | -107.00 | 179.00 | 96.00 | -441.00 | 31.00 | 201.00 | 152.60 |
| Weighted Avg Shares Out | 22.87M | 23.00M | 23.37M | 23.47M | 23.06M | 19.61M | 19.83M | 19.93M | 19.78M | 18.59M | 18.07M | 17.64M | 17.66M | 18.00M | 18.34M | 18.19M | 17.40M |
| Weighted Avg Shares Out (Dil) | 23.91M | 24.18M | 23.40M | 23.47M | 23.06M | 19.61M | 19.83M | 20.01M | 19.78M | 18.91M | 18.58M | 17.83M | 17.66M | 18.00M | 18.34M | 18.19M | 17.40M |
Source: https://incomestatements.info
Category: Stock Reports